FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386986241> ?p ?o ?g. }

• W4386986241 endingPage "S122" @default.
• W4386986241 startingPage "S122" @default.
• W4386986241 abstract "Purpose To compare the efficacy and safety of radioactive I-125 seed ablation brachytherapy (RSABT) and microwave ablation therapy (MWAT) in the treatment of inoperable early non-small cell lung cancer. Materials and Methods The data of patients with early non-small cell lung cancer who received CT guided RSABT and MWAT in our collaborative group from December 2010 to November 2020 were included. The main outcome measure was progression free survival, and the secondary outcome measures were overall survival rate and adverse events. Kaplan-Meier methods were used to analyze progression free survival and overall survival. Logistic and Cox regression were used for univariate and multivariate analysis, respectively. Results The median follow-up time of patients in RSABT and MWAT groups were 47.4 months and 60 months, respectively. Progression free survival (PFS) in the RSABT group was better than that in the MWAT group. The 1-year, 3-year and 5-year PFS of RSABT and MWAT group were 87.3%, 72.6%, 65.8% and 89.5%, 69.3% and 43.7% respectively (P = 0.011); the overall survival (OS) of RSABT group was slightly better than MWAT group. The 1-year, 3-year and 5-year OS of the two groups were 97.2%, 78.1%, 66.1% and 99%, 75.8% and 55% respectively (P = 0.112). Treatment technology was also an independent factor affecting PFS (HR 0.48, 95%CI 0.28-0.83, P=0.008) in multivariate Cox analysis. And gender and T stage were independent factors affecting PFS and OS (P < 0.05). There are no fatal operation related complications. Pneumothorax was the most common complication. The incidence of MWAT group was slightly higher than that of RSABT group, which were 50% and 39% respectively (P = 0.313). The incidence of pleural effusion in MWAT group was higher than that in RSABT group (44% and 14%, respectively, P < 0.001). The incidence of needle bleeding in RSABT group was higher than that in MWAT group (32% and 5%, respectively, P < 0.001). Conclusions The outcomes of RSABT in the treatment of early NSCLC is no less than MWAT, and the incidence of operation complications is also equivalent to MWAT, but further exploration is needed. To compare the efficacy and safety of radioactive I-125 seed ablation brachytherapy (RSABT) and microwave ablation therapy (MWAT) in the treatment of inoperable early non-small cell lung cancer. The data of patients with early non-small cell lung cancer who received CT guided RSABT and MWAT in our collaborative group from December 2010 to November 2020 were included. The main outcome measure was progression free survival, and the secondary outcome measures were overall survival rate and adverse events. Kaplan-Meier methods were used to analyze progression free survival and overall survival. Logistic and Cox regression were used for univariate and multivariate analysis, respectively. The median follow-up time of patients in RSABT and MWAT groups were 47.4 months and 60 months, respectively. Progression free survival (PFS) in the RSABT group was better than that in the MWAT group. The 1-year, 3-year and 5-year PFS of RSABT and MWAT group were 87.3%, 72.6%, 65.8% and 89.5%, 69.3% and 43.7% respectively (P = 0.011); the overall survival (OS) of RSABT group was slightly better than MWAT group. The 1-year, 3-year and 5-year OS of the two groups were 97.2%, 78.1%, 66.1% and 99%, 75.8% and 55% respectively (P = 0.112). Treatment technology was also an independent factor affecting PFS (HR 0.48, 95%CI 0.28-0.83, P=0.008) in multivariate Cox analysis. And gender and T stage were independent factors affecting PFS and OS (P < 0.05). There are no fatal operation related complications. Pneumothorax was the most common complication. The incidence of MWAT group was slightly higher than that of RSABT group, which were 50% and 39% respectively (P = 0.313). The incidence of pleural effusion in MWAT group was higher than that in RSABT group (44% and 14%, respectively, P < 0.001). The incidence of needle bleeding in RSABT group was higher than that in MWAT group (32% and 5%, respectively, P < 0.001). The outcomes of RSABT in the treatment of early NSCLC is no less than MWAT, and the incidence of operation complications is also equivalent to MWAT, but further exploration is needed." @default.
• W4386986241 created "2023-09-24" @default.
• W4386986241 creator A5011264334 @default.
• W4386986241 creator A5019288987 @default.
• W4386986241 creator A5021005715 @default.
• W4386986241 creator A5046678038 @default.
• W4386986241 creator A5048989648 @default.
• W4386986241 creator A5081884581 @default.
• W4386986241 date "2023-09-01" @default.
• W4386986241 modified "2023-10-16" @default.
• W4386986241 title "PO107" @default.
• W4386986241 doi "https://doi.org/10.1016/j.brachy.2023.06.208" @default.
• W4386986241 hasPublicationYear "2023" @default.
• W4386986241 type Work @default.
• W4386986241 citedByCount "0" @default.
• W4386986241 crossrefType "journal-article" @default.
• W4386986241 hasAuthorship W4386986241A5011264334 @default.
• W4386986241 hasAuthorship W4386986241A5019288987 @default.
• W4386986241 hasAuthorship W4386986241A5021005715 @default.
• W4386986241 hasAuthorship W4386986241A5046678038 @default.
• W4386986241 hasAuthorship W4386986241A5048989648 @default.
• W4386986241 hasAuthorship W4386986241A5081884581 @default.
• W4386986241 hasConcept C10515644 @default.
• W4386986241 hasConcept C126322002 @default.
• W4386986241 hasConcept C143998085 @default.
• W4386986241 hasConcept C144301174 @default.
• W4386986241 hasConcept C146357865 @default.
• W4386986241 hasConcept C151730666 @default.
• W4386986241 hasConcept C151956035 @default.
• W4386986241 hasConcept C2776256026 @default.
• W4386986241 hasConcept C2776283816 @default.
• W4386986241 hasConcept C2777416452 @default.
• W4386986241 hasConcept C2778014663 @default.
• W4386986241 hasConcept C2778902805 @default.
• W4386986241 hasConcept C2780739268 @default.
• W4386986241 hasConcept C3019894029 @default.
• W4386986241 hasConcept C38180746 @default.
• W4386986241 hasConcept C50382708 @default.
• W4386986241 hasConcept C509974204 @default.
• W4386986241 hasConcept C71924100 @default.
• W4386986241 hasConcept C86803240 @default.
• W4386986241 hasConceptScore W4386986241C10515644 @default.
• W4386986241 hasConceptScore W4386986241C126322002 @default.
• W4386986241 hasConceptScore W4386986241C143998085 @default.
• W4386986241 hasConceptScore W4386986241C144301174 @default.
• W4386986241 hasConceptScore W4386986241C146357865 @default.
• W4386986241 hasConceptScore W4386986241C151730666 @default.
• W4386986241 hasConceptScore W4386986241C151956035 @default.
• W4386986241 hasConceptScore W4386986241C2776256026 @default.
• W4386986241 hasConceptScore W4386986241C2776283816 @default.
• W4386986241 hasConceptScore W4386986241C2777416452 @default.
• W4386986241 hasConceptScore W4386986241C2778014663 @default.
• W4386986241 hasConceptScore W4386986241C2778902805 @default.
• W4386986241 hasConceptScore W4386986241C2780739268 @default.
• W4386986241 hasConceptScore W4386986241C3019894029 @default.
• W4386986241 hasConceptScore W4386986241C38180746 @default.
• W4386986241 hasConceptScore W4386986241C50382708 @default.
• W4386986241 hasConceptScore W4386986241C509974204 @default.
• W4386986241 hasConceptScore W4386986241C71924100 @default.
• W4386986241 hasConceptScore W4386986241C86803240 @default.
• W4386986241 hasIssue "5" @default.
• W4386986241 hasLocation W43869862411 @default.
• W4386986241 hasOpenAccess W4386986241 @default.
• W4386986241 hasPrimaryLocation W43869862411 @default.
• W4386986241 hasRelatedWork W2013727445 @default.
• W4386986241 hasRelatedWork W2361700749 @default.
• W4386986241 hasRelatedWork W2363865786 @default.
• W4386986241 hasRelatedWork W2369074925 @default.
• W4386986241 hasRelatedWork W2374376758 @default.
• W4386986241 hasRelatedWork W2394214356 @default.
• W4386986241 hasRelatedWork W2784206856 @default.
• W4386986241 hasRelatedWork W2890272496 @default.
• W4386986241 hasRelatedWork W3014880994 @default.
• W4386986241 hasRelatedWork W3032885188 @default.
• W4386986241 hasVolume "22" @default.
• W4386986241 isParatext "false" @default.
• W4386986241 isRetracted "false" @default.
• W4386986241 workType "article" @default.